Table of Contents
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information Or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Strong Pipeline of Oligonucleotide Therapeutics in Clinical Trials
3.2.1.2. Changing Regulatory Environments For Genetic Research And Its Applications In Healthcare
3.2.1.3. High R & D Spending of Pharmaceutical – Biotechnology Companies
3.2.1.4. Increased Public-Private Spending on Genomics
3.2.1.5. Technological Advancements in Gene Editing Technologies
3.2.2. Market Restraint Analysis
3.2.2.1. Need For Advanced Oligo Synthesis Solutions
3.2.2.2. High Cost Associated with Genomics Research
3.2.2.3. Lack Of Skilled Professionals And Research Support In Undeveloped Countries
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Oligonucleotide Synthesis Market: Product Movement Analysis
4.2. Oligonucleotides
4.2.1. Oligonucleotides Market, 2018 – 2030 (USD Million)
4.2.2. Oligonucleotides, By Product Type
4.2.2.1 Column-Based Oligos
4.2.2.1.1 Global Column-Based Oligos Market, 2018 – 2030 (USD Million)
4.2.2.2 Array-Based Oligos
4.2.2.2.1 Global Array-Based Oligos Market, 2018 – 2030 (USD Million)
4.2.3. Oligonucleotides, By Nucleic Acid Type
4.2.3.1 DNA Oligos
4.2.3.1.1 Global DNA Oligo Market, 2018 – 2030 (USD Million)
4.2.3.2 RNA Oligos
4.2.3.2.1 Global RNA Oligo Market, 2018 – 2030 (USD Million)
4.3. Equipment/ Synthesizers
4.3.1. Global Oligonucleotide Synthesis Equipment Market, 2018 – 2030 (USD Million)
4.4. Reagents
4.4.1. Global Oligonucleotide Synthesis Reagents Market, 2018 – 2030 (USD Million)
4.5. Services
4.5.1. Global Oligonucleotide Services Market, 2018 – 2030 (USD Million)
4.5.2. Oligo Synthesis
4.5.2.1. Global Oligo Synthesis Services Market, 2018 – 2030 (USD Million)
4.5.2.2. 25 nmol
4.5.2.2.1. Global 25 Nmol Oligo Synthesis Services Market, 2018 – 2030 (USD Million)
4.5.2.3. 50 nmol
4.5.2.3.1. Global 50 Nmol Oligo Synthesis Services Market, 2018 – 2030 (USD Million)
4.5.2.4. 200 nmol
4.5.2.4.1. Global 200 Nmol Oligo Synthesis Services Market, 2018 – 2030 (USD Million)
4.5.2.5. 1,000 nmol
4.5.2.5.1. Global 1,000 nmol Oligo Synthesis Services Market, 2018 – 2030 (USD Million)
4.5.2.6. 10,000 nmol
4.5.2.6.1. Global 10,000 nmol Oligo Synthesis Services Market, 2018 – 2030 (USD Million)
4.5.3. Purification
4.5.3.1. Global Oligonucleotide Purification Services Market, 2018 – 2030 (USD Million)
4.5.4. Modification
4.5.4.1. Global Oligonucleotide Modification Services Market, 2018 – 2030 (USD Million)
Chapter 5. Application Business Analysis
5.1. Oligonucleotide Synthesis Market: Application Movement Analysis
5.2. PCR Primers
5.2.1. PCR Primers Market, 2018 – 2030 (USD Million)
5.3. PCR Assays and Panels
5.3.1. PCR Assays and Panels Market, 2018 – 2030 (USD Million)
5.4. Sequencing
5.4.1. Sequencing Market, 2018 – 2030 (USD Million)
5.5. DNA Microarrays
5.5.1. DNA Microarrays Market, 2018 – 2030 (USD Million)
5.6. Fluorescence In Situ Hybridization (FISH)
5.6.1. Fluorescence In Situ Hybridization (FISH) Market, 2018 – 2030 (USD Million)
5.7. Antisense Oligonucleotides
5.7.1. Antisense Oligonucleotides Market, 2018 – 2030 (USD Million)
5.8. Other Applications
5.8.1. Other Applications Market, 2018 – 2030 (USD Million)
Chapter 6. End-User Business Analysis
6.1. Oligonucleotide Synthesis Market: End-User Movement Analysis
6.2. Academic and Research Institutes
6.2.1. Academic and Research Institutes Market, 2018 – 2030 (USD Million)
6.3. Pharmaceutical & Biotechnology Companies
6.3.1. Pharmaceutical & Biotechnology Companies Market, 2018 – 2030 (USD Million)
6.4. Diagnostic Laboratories
6.4.1. Diagnostic Laboratories Market, 2018 – 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Oligonucleotide Synthesis Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. SWOT Analysis
7.2.2. North America Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.2.3. U.S.
7.2.3.1. Key Country Dynamics
7.2.3.2. Regulatory Framework
7.2.3.3. Competitive Scenario
7.2.3.4. U.S. Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.2.4. Canada
7.2.4.1. Key Country Dynamics
7.2.4.2. Regulatory Framework
7.2.4.3. Competitive Scenario
7.2.4.4. Canada Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.3. Europe
7.3.1. SWOT Analysis
7.3.2. Europe Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.3.3. UK
7.3.3.1. Key Country Dynamics
7.3.3.2. Regulatory Framework
7.3.3.3. Competitive Scenario
7.3.3.4. UK Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.3.4. Germany
7.3.4.1. Key Country Dynamics
7.3.4.2. Regulatory Framework
7.3.4.3. Competitive Scenario
7.3.4.4. Germany Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.3.5. France
7.3.5.1. Key Country Dynamics
7.3.5.2. Regulatory Framework
7.3.5.3. Competitive Scenario
7.3.5.4. France Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.3.6. Italy
7.3.6.1. Key Country Dynamics
7.3.6.2. Regulatory Framework
7.3.6.3. Competitive Scenario
7.3.6.4. Italy Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.3.7. Spain
7.3.7.1. Key Country Dynamics
7.3.7.2. Regulatory Framework
7.3.7.3. Competitive Scenario
7.3.7.4. Spain Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.3.8. Denmark
7.3.8.1. Key Country Dynamics
7.3.8.2. Regulatory Framework
7.3.8.3. Competitive Scenario
7.3.8.4. Denmark Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.3.9. Sweden
7.3.9.1. Key Country Dynamics
7.3.9.2. Regulatory Framework
7.3.9.3. Competitive Scenario
7.3.9.4. Sweden Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.3.10. Norway
7.3.10.1. Key Country Dynamics
7.3.10.2. Regulatory Framework
7.3.10.3. Competitive Scenario
7.3.10.4. Norway Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.4. Asia Pacific
7.4.1. SWOT Analysis
7.4.2. Asia Pacific Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Scenario
7.4.3.4. Japan Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.4.4. China
7.4.4.1. Key Country Dynamics
7.4.4.2. Regulatory Framework
7.4.4.3. Competitive Scenario
7.4.4.4. China Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.4.5. India
7.4.5.1. Key Country Dynamics
7.4.5.2. Regulatory Framework
7.4.5.3. Competitive Scenario
7.4.5.4. India Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Key Country Dynamics
7.4.6.2. Regulatory Framework
7.4.6.3. Competitive Scenario
7.4.6.4. Australia Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Key Country Dynamics
7.4.7.2. Regulatory Framework
7.4.7.3. Competitive Scenario
7.4.7.4. Thailand Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.4.8. South Korea
7.4.8.1. Key Country Dynamics
7.4.8.2. Regulatory Framework
7.4.8.3. Competitive Scenario
7.4.8.4. South Korea Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.5. Latin America
7.5.1. SWOT Analysis
7.5.2. Latin America Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.5.3. Brazil
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Scenario
7.5.3.4. Brazil Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.5.4. Mexico
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Scenario
7.5.4.4. Mexico Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.5.5. Argentina
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Scenario
7.5.5.4. Argentina Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.6. MEA
7.6.1. SWOT Analysis
7.6.2. MEA Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.6.3. South Africa
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Scenario
7.6.3.4. South Africa Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.6.4. Saudi Arabia
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Scenario
7.6.4.4. Saudi Arabia Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.6.5. UAE
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Scenario
7.6.5.4. UAE Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
7.6.6. Kuwait
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Scenario
7.6.6.4. Kuwait Oligonucleotide Synthesis Market, 2018 – 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2022
8.4. Company Profiles/Listing
8.4.1. Thermo Fisher Scientific, Inc.
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Merck & Co. Inc
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. PerkinElmer Inc.
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Agilent Technologies, Inc
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Bio-synthesis, Inc.
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Kaneka Eurogentec S.A
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Integrated DNA Technologies, Inc.
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. BioAutomation (BIOSEARCH TECHNOLOGIES)
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Biolegio
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Twist Bioscience
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/